A R T I C L E S
Scheme 3. Total Syntheses of Strongylodiols A and B
Figure 3. Structural similarity of 17 and falcarindiol.
Scheme 5. Total Synthesis of (3S,8S)-17a
Scheme 4. Total Synthesis of (3R,9R,10R)-Panaxytriol (14)a
a Conditions: (a) 1) Ac2O, Et3N, 10 mol % DMAP, CH2Cl2; 2) Bu4N+F-,
AcOH, THF, 0 °C, 70% over 2 steps; (b) decyl aldehyde, 20 mol % (R,R)-
1, 40 mol % TPPO, 3 equiv Me2Zn, toluene, 4 °C, 67%.
also interested in constructing a molecule using sequential
asymmetric diynylations. 8-Hydroxyheptadeca-1-en-4,6-diyn-
3-yl ethanoate (17), an unnamed natural product, was an ideal
target with which to demonstrate this principle (Figure 3).
Isolated from the Tanzanian medicinal plant Cussonia zimmer-
mannii, polyacetylene 17 exhibited potent antiprotozoal activity
and also cytotoxicity.27 Although the structure was elucidated
by NMR spectroscopy, no stereochemical assignment was
reported. As this molecule had not been previously synthesized,
a total synthesis would serve to confirm the structural assignment
and establish the absolute and relative stereochemistry. Given
the structural similarity of 17 with (3S,8S)-falcarindiol,28 we
hypothesized the target compound also possesses the (3S,8S)-
configuration.
Since (S,S)-ProPhenol (1) affords the (R)-diynol, use of the
(R,R)-enantiomer was required to prepare ent-6c with the correct
stereochemistry (Scheme 5). The absolute configuration of the
diyne addition was verified by the O-methylmandelate ester
method.29,30 Treatment of ent-6c with acetic anhydride, followed
by cleavage of the TIPS group with TBAF, furnished 18 in 70%
yield. The resulting terminal diyne was then utilized in a
subsequent ProPhenol-catalyzed diynylation; this double-bar-
reled approach allows for the rapid construction of two
challenging stereocenters. Under the reaction conditions with
catalytic (R,R)-1 and TPPO, diyne 18 coupled with decyl
aldehyde to furnish polyacetylene 17 in 67% yield.
a Conditions: (a) Bu4N+F-, THF, 0 °C, >99%; (b) 1) BuLi, THF, -78
°C, then BF3 ·Et2O; 2) 16, THF; 3) Bu4N+F-, 70%.
cancer cell lines.23 Furthermore, recent studies have shown that
the anticancer properties of 14 are a result of a cytoprotective
mechanism.24,25 Due to its important biological properties, many
total syntheses of panaxytriol have been accomplished,26 where
the C3 stereocenter has been derived from sugar degradation,26a,b,e
enzymatic resolution,26d or asymmetric ynone reduction,26f,g but
not through direct asymmetric diyne addition (Scheme 4).
Treatment of diynol 6c, formed in 86% ee from the addition
of TIPS diyne 4 into acrolein, with TBAF revealed terminal
diyne 15. Next, double deprotonation of 15 with BuLi generated
the dianion which was complexed with BF3 ·Et2O to form the
diynyl borate. The reaction of this acetylide with siloxy epoxide
16 led to regioselective ring-opening of the epoxide. An in situ
quench of the ring-opened intermediate with TBAF furnished
(3R,9R,10R)-panaxytriol in 70% yield. This lynchpin diynylation
strategy not only allowed for rapid enantioselective construction
of the diyne carbinol, but also facile coupling of two chiral
fragments without the need to discretely preactivate either piece.
Through our sequence, (3R,9R,10R)-panaxytriol was prepared
in 70% yield over three steps from acrolein.
In the synthesis of panaxytriol, a chiral diynol was coupled
with a fragment containing its own chirality; however, we were
The measured optical rotation of the synthetic natural product
was consistent with the literature report, confirming our
hypothesis that naturally occurring 17 is of the (3S,8S)-
configuration. Furthermore, the stereochemistry of the propargyl
alcohol at C8 was verified using the O-methylmandelate ester
method;30 this derivitization also revealed the diastereoselectivity
(>8.2:1 dr) of the second addition. Also of note is that the chiral
acetoxy group in diyne 18 did not appear to interfere with the
stereoselectivity of the second diynylation. Since the formation
of the two stereogenic centers was catalyst controlled, the other
(22) (a) Kitagawa, I.; Yoshikawa, M.; Yoshihara, M.; Hayashi, T.;
Taniyama, T. Yakugaku Zasshi 1983, 103, 612–622. (b) Kitagawa, I.;
Taniyama, T.; Shibuya, H.; Noda, T.; Yoshikawa, M. Yakugaku Zasshi
1987, 107, 495–505.
(23) (a) Katano, M.; Yamamoto, H.; Matsunaga, H.; Mori, M.; Takata,
K.; Nakamura, M. Gan to Kagaku Ryoho 1990, 17, 1045–1049. (b)
Matsunaga, H.; Saita, T.; Naguo, F.; Mori, M.; Katano, M. Cancer
Chemother. Pharmacol. 1995, 35, 291–296. (c) Saita, T.; Katano, M.;
Matsunaga, H.; Kouno, I.; Fujito, H.; Mori, M. Biol. Pharm. Bull.
1995, 18, 933–937. (d) Kim, J. Y.; Lee, K.-W.; Kim, S.-H.; Wee,
J. J.; Kim, Y.-S.; Lee, H. J. Planta Med. 2002, 68, 119–122.
(24) Halim, M.; Yee, D. J.; Sames, D. J. Am. Chem. Soc. 2008, 130, 14123–
14128.
(25) Ng, F.; Yun, H.; Lei, X.; Danishefsky, S. J.; Fahey, J.; Stephenson,
K.; Flexner, C.; Lee, L. Tetrahedron Lett. 2008, 49, 7178–7179.
(26) (a) Lu, W.; Zheng, G.; Cai, J. Synlett 1998, 737–738. (b) Lu, W.;
Zheng, G.; Gao, D.; Cai, J. Tetrahedron 1999, 55, 7157–7168. (c)
Gurjar, M. K.; Kumar, V. S.; Rao, B. V. Tetrahedron 1999, 55, 12563–
12576. (d) Mayer, S. F.; Steinreiber, A.; Orru, R. V. A.; Faber, K. J.
Org. Chem. 2002, 67, 9115–9121. (e) Yadav, J. S.; Maiti, A.
Tetrahedron 2002, 58, 4955–4961. (f) Yun, H.; Danishefsky, S. J. J.
Org. Chem. 2003, 68, 4519–4522. (g) Yun, H.; Chou, T.-C.; Dong,
H.; Tian, Y.; Li, Y.-M.; Danishefsky, S. J. J. Org. Chem. 2005, 70,
10375–10380. (h) Cho, E. J.; Lee, D. Org. Lett. 2008, 10, 257–259.
(27) (a) Baur, R.; Simmen, U.; Senn, M.; Se´quin, U.; Sigel, E. Mol.
Pharmacol. 2005, 68, 787–792. (b) Senn, M.; Gunzenhauser, S.; Brun,
R.; Se´quin, U. J. Nat. Prod. 2007, 70, 1565–1569.
(28) Bernart, M. W.; Cardellina, J. H., II; Balaschak, M. S.; Alexander,
M. R.; Shoemaker, R. H.; Boyd, M. R. J. Nat. Prod. 1996, 59, 748–
753.
(29) Trost, B. M.; Belletire, J. L.; Godleski, S.; McDougal, P. G.; Balkovec,
J. M. J. Org. Chem. 1986, 51, 2370–2374.
(30) See the Supporting Information for analysis of the O-methylmandelate
esters.
9
J. AM. CHEM. SOC. VOL. 132, NO. 14, 2010 5191